{"id":860355,"date":"2025-06-13T07:40:39","date_gmt":"2025-06-13T11:40:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/"},"modified":"2025-06-13T07:40:39","modified_gmt":"2025-06-13T11:40:39","slug":"altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/","title":{"rendered":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions"},"content":{"rendered":"
\n

GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc.<\/a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association\u2019s (ADA) 85th<\/sup> Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1\/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).<\/p>\n

Details for the oral presentation are as follows:<\/p>\n\n\n\n\n\n\n
\n Session Title:<\/strong>\n <\/td>\nEarly Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies \u2013 Take 1<\/td>\n<\/tr>\n
\n Session Date\/Time:<\/strong>\n <\/td>\nSaturday, June 21, 2025, 4:30 PM – 6:00 PM CDT<\/td>\n<\/tr>\n
\n Presentation Title:<\/strong>\n <\/td>\nEffects of Pemvidutide, a GLP-1\/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nJohn J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune<\/td>\n<\/tr>\n
\n Presentation Date\/Time:<\/strong>\n <\/td>\nSaturday, June 21, 2025 at 5:45 PM CDT<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

Details of the poster presentations are as follows:<\/p>\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nIntegrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nShaheen Tomah, M.D., Director, Clinical Development, Altimmune<\/td>\n<\/tr>\n
\n Presentation Date\/Time:<\/strong>\n <\/td>\nSunday, June 22, 2025, 12:30 PM – 1:30 PM CDT<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nNon-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nShaheen Tomah, M.D., Director, Clinical Development, Altimmune<\/td>\n<\/tr>\n
\n Presentation Date\/Time:<\/strong>\n <\/td>\nSunday, June 22, 2025, 12:30 PM – 1:30 PM CDT<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nPemvidutide, a Balanced GLP-1\/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)<\/td>\n<\/tr>\n
\n Presenter:<\/strong>\n <\/td>\nJohn J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune<\/td>\n<\/tr>\n
\n Presentation Date\/Time:<\/strong>\n <\/td>\nSunday, June 22, 2025, 12:30PM – 1:30 PM CDT<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n

These presentations will be accessible on the Events<\/a> section of the Altimmune website.<\/p>\n

\n About Pemvidutide<\/strong>
\n
Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1\/glucagon dual receptor agonist in development for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide completed the MOMENTUM Phase 2 obesity trial in 2024 and is being studied in the ongoing IMPACT Phase 2b MASH trial with top line results expected in Q2 2025. IND applications in AUD and ALD have received FDA clearance with the Phase 2 trial in AUD having commenced in Q2 2025 and the ALD trial scheduled to commence in Q3 2025.<\/p>\n

\n About Altimmune
<\/strong>Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company\u2019s lead program is pemvidutide, a GLP-1\/glucagon dual receptor agonist for the treatment of MASH, obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com<\/a>.<\/p>\n

\n Follow @Altimmune, Inc. on <\/strong>
\n
\n LinkedIn<\/strong>
\n <\/a>
\n
\n Follow @AltimmuneInc on <\/strong>
\n
\n Twitter<\/strong>
\n <\/a>\n <\/p>\n

\n Company Contact:<\/strong>
\n
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com<\/a><\/p>\n

\n Investor Contact:<\/strong>
\n
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
jake.robison@inizioevoke.com<\/a><\/p>\n

This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association\u2019s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1\/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral presentation are as follows: Session Title: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies \u2013 Take 1 Session Date\/Time: Saturday, June 21, 2025, 4:30 PM – … <\/p>\n

Continue reading “Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860355","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAltimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association\u2019s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1\/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral presentation are as follows: Session Title: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies \u2013 Take 1 Session Date\/Time: Saturday, June 21, 2025, 4:30 PM – … Continue reading "Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-13T11:40:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions\",\"datePublished\":\"2025-06-13T11:40:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/\"},\"wordCount\":604,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/\",\"name\":\"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=\",\"datePublished\":\"2025-06-13T11:40:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk","og_description":"GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association\u2019s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1\/glucagon dual receptor agonist under development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). Details for the oral presentation are as follows: Session Title: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies \u2013 Take 1 Session Date\/Time: Saturday, June 21, 2025, 4:30 PM – … Continue reading \"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-13T11:40:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions","datePublished":"2025-06-13T11:40:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/"},"wordCount":604,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/","name":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=","datePublished":"2025-06-13T11:40:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODEyMSM2OTg5NTM5IzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-multiple-presentations-at-upcoming-american-diabetes-associations-scientific-sessions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association\u2019s Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860355"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860355\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}